Objectives: Hemodynamic vulnerability after the Norwood procedure for hypoplastic left heart syndrome results from impaired myocardial function, and critical inefficiency of parallel circulation. Traditional management strategies have attempted to optimize circulatory efficiency by using arterial oxygen saturation (SaO 2 ) as an index of pulmonary/systemic flow balance, attempting to maintain SaO 2 within a theoretically optimal critical range of 75% to 80%. This optimal range of SaO 2 has not been verified clinically, and strategies targeting SaO 2 may be limited by the fact that SaO 2 is a poor predictor of systemic oxygen delivery. We have previously reported higher venous saturation (SvO 2 ), lower arteriovenous oxygen content difference, lower systemic vascular resistance, lower pulmonary/systemic flow ratio, and improved survival with the perioperative use of phenoxybenzamine and continuous monitoring of SvO 2 . In this investigation, we tested the hypothesis that intense afterload reduction with phenoxybenzamine would modify the SvO 2 -SaO 2 relationship by preventing deterioration of systemic oxygen delivery at high SaO 2 .
C ardiogenic shock remains a major cause of morbidity after the Norwood procedure. Following the Norwood procedure, the neonate has a unique convergence of physiologic vulnerabilities: myocardial dysfunction after ischemia, reperfusion, and cardiopulmonary bypass (CPB), potential limitations of a morphologically right ventricle, potential aorta-coronary flow limitation, and intrinsic inefficiency of parallel circulation. 1, 2 Management of the interactions of these multiple vulnerabilities in the postoperative period is complex and has been approached both theoretically via circulatory models and empirically by direct measurement of additional physiologic parameters such as systemic venous saturation (SvO 2 ) 1, 3, 4 in an attempt to avoid or detect hemodynamic deterioration before cardiovascular collapse.
Several models with differing assumptions about complex univentricular circulation have been developed to guide management when clinical data are incomplete. Norwood and colleagues 1, 2, 5 have argued that maintenance of arterial saturation (SaO 2 ) in the 75% to 80% range would optimize circulatory efficiency with a resulting SvO 2 of 50% to 60% and pulmonary/systemic flow ratio (Qp/Qs) near 1.0. This management strategy is based largely on circulatory modeling with a constant arteriovenous oxygen content difference, but highly variable Qp/Qs and therefore SaO 2 .
1,2,5,6 Alternatively, the SaO 2 -SvO 2 relationship has been modeled at constant total cardiac output, with variable Qp/Qs and systemic flow, also resulting in a narrow optimum range of SaO 2 to maximize SvO 2 or systemic oxygen delivery. 6 In either case, the circulatory models predict a critical range of SaO 2 for optimal circulatory efficiency, but the exact target SaO 2 remains dependent on other parameters such as oxygen consumption (VO 2 ), cardiac output, and hemoglobin, as well as knowledge of Qp/Qs to fully resolve the resulting SvO 2 . 6 Strategies to balance the circulation have typically relied on manipulation of medical gases to raise pulmonary vascular resistance (PVR) and restrict SaO 2 to the target range of 75% to 80%. 1, 2, 5, [7] [8] [9] [10] In a less restrictive model assuming complete systemic and pulmonary mixing, and permitting variability in both Qp/Qs and total cardiac output, we demonstrated a wide range of SvO 2 at any SaO 2 , and the essential lack of predictability of SvO 2 from SaO 2 .
11 This theoretical inadequacy of SaO 2 as a predictor of SvO 2 , the intrinsic contradictions and complexities of management strategies which rely on SaO 2 limitation as a means of maximizing oxygen delivery, and less than optimal outcomes using approaches based on prediction of SvO 2 from SaO 2 , motivated us to search for a better management method. Direct, continuous measurement of SvO 2 allowed the detection of critical reductions in systemic oxygen delivery and provided additional data to more closely estimate Qp/Qs and guide subsequent intervention. 3, 12 We observed wide variability in SvO 2 despite maintenance of SaO 2 in the traditional target range, 12, 13 emphasizing the dynamic relationships between reduction in systemic oxygen delivery, reflex elevation in systemic vascular resistance (SVR), systemic-pulmonary flow tradeoff, and further reductions in systemic perfusion with systemic vasoconstriction, which, if unchecked, would lead to overt failure of systemic perfusion.
We hypothesized that the relevance of increases in SVR as a cause of instability after the Norwood procedure could be confirmed by examination of the relationship between SaO 2 and SvO 2 for evidence of deterioration of systemic oxygenation at higher SaO 2 . In this investigation, we analyzed our prospectively collected physiologic database to attempt to confirm the existence of a critical SaO 2 range to maximize SvO 2 , and to test the hypothesis that this relationship would be altered by intense afterload reduction with phenoxybenzamine.
Materials and Methods

Patient Population and Management Strategy
All patients undergoing the Norwood procedure for hypoplastic left heart syndrome from July 1996 to July 2000 were included in this study. After appropriate preoperative stabilization, all patients underwent surgical palliation consisting of anastomosis of the pulmonary artery to the ascending aorta combined with augmentation of the ascending aorta, transverse arch, and proximal descending aorta with pulmonary homograft, placement of a systemic-pulmonary artery shunt (3.0-4.5 mm), and creation of a nonrestrictive atrial septal defect. 12 This procedure was performed with synthetic opioid-based perioperative anesthesia, 14 hypothermic CPB with pH-stat blood gas management to facilitate cooling to a temperature of 26°C, ␣-stat management before and after circulatory arrest at 16°C to 18°C, and modified ultrafiltration. On initiation of CPB, phenoxybenzamine 0.25 mg/kg was administered to 62 of 71 infants according to a prospective nonrandomized surgeon-directed protocol with Food and Drug Administration and institutional review board approval and parental informed consent. During rewarming, all patients received milrinone 50 ⅐ kg Ϫ1 followed by infusions of milrinone at 0.5 · kg Ϫ1 · min Ϫ1 and dopamine at 3 · kg Ϫ1 · min Ϫ1 . Oximetric catheters (4F OxyCath, Abbott Laboratories, N Chicago, Ill) were surgically placed in the superior vena cava (SVC) to allow continuous monitoring of SvO 2 . Before separation from CPB, infusions of nitroprusside or norepinephrine were titrated to achieve an approximate SVR index of 12 Wood units (mean arterial pressure of 40 mm Hg at CPB flow index of 3.2 L/m 2 /min), and epinephrine was added for additional inotropic support if necessary. Patients were transported to the pediatric intensive care unit (ICU) after hemostasis for postoperative management, which included routine delayed sternal closure.
Postoperative management targets included mean arterial blood pressure (MAP) greater than 45 mm Hg, SvO 2 greater than 50%, SaO 2 70% to 85%, and clinical evidence of end-organ function (urine output of at least 1 mL · kg Ϫ1 · h Ϫ1 , biochemical evidence of adequate gluconeogenesis, and behavioral responses after withdrawal of neuromuscular blockade). Systemic diastolic pressure was not specifically targeted unless electrophysiologic evidence of ischemia was present with continuous ST analysis (Solar 3000, Marquette Electronics Inc, Milwaukee, Wis). All patients received continuous fentanyl infusions at 5 to 10 g · kg Ϫ1 · h Ϫ1 , and neuromuscular blockade was maintained by vecuronium infusion until postoperative day 1. A normothermic environment was maintained with servo controlled warmers (Ohio Infant Warmer System, Ohmeda Inc, Columbia, Md). Ventilator settings were adjusted to maintain arterial normocapnia (PaCO 2 35 to 45 mm Hg) with inflating pressures of 24 to 28 cm H 2 O, positive end-expiratory pressure of 4 to 5 cm H 2 O, and an FIO 2 of 0.3 to 1.0 to assure fully saturated pulmonary capillary blood. 15 Specifically, room air was not used as a ventilating gas, and FIO 2 was adjusted to maximize SvO 2 . Low SvO 2 (40% or less) with Qp/Qs near 2.0 or greater was addressed by attempts to lower SVR with additional analgesia or sedation, nitroprusside, or, in patients who had received phenoxybenzamine on CPB, initiation of a phenoxybenzamine infusion (0.25 mg/kg per day or 10 g · kg Ϫ1 · h Ϫ1 ). A low SvO 2 with Qp/Qs near 1.0 was addressed by transfusion of red cells to achieve a hematocrit value in the 45% to 50% range, and additional inotropic support when necessary.
Monitoring and Data Collection
A prospective perioperative database for all patients undergoing the Norwood repair for hypoplastic left heart syndrome since July 1996 was maintained for demographic, surgical, and 48-hour postoperative hemodynamic and laboratory data. Physiologic parameters included invasive arterial (MAP) and atrial pressures (RAP), arterial saturation (N-200, Nellcor, Haywood, Calif), inspired oxygen and end-tidal carbon dioxide tension, and oximetric SvO 2 from the SVC as an approximation of mixed venous saturation. 1, 16 These parameters were continuously displayed, digitally acquired, and averaged using either a dedicated personal computer-based monitoring cart (DAP-102; Microstar Labs, Belleview, Wash; DasyLab, DasyTec GmBH, Concord, NH) or a multichannel clinical information system (Marquette Solar). Arterial and venous blood gases and co-oximetry (ABL, Radiometer, Copenhagen, Denmark) were obtained at clinically appropriate intervals. The physiologic parameters, laboratory data, ventilator parameters, and medication infusion rates were recorded hourly for the first 48 postoperative hours with a standardized, prospective data record.
From measurements of SaO 2 , SvO 2 , MAP, RAP, and hemoglobin concentration, hemodynamic and oxygen transport indices were derived according to standard formulas. These derived parameters included arteriovenous O 2 difference in saturation (⌬Sa-vO 2 ) and content (⌬Ca-vO 2 ), as well as oxygen extraction ratio (O 2 ER, [⌬Sa-vO 2 ]/SaO 2 ), and oxygen excess factor (⍀ SaO 2 / [⌬Sa-vO 2 ]), both flow-independent indices of systemic oxygen status. Pulmonary/systemic flow ratio (Qp/Qs) was calculated from SaO 2 and SvO 2 using an assumed pulmonary capillary saturation of 97%. 3, 4, 12, 15 Additional parameters derived from an assumed oxygen consumption of 160 mL · min Ϫ1 · m Ϫ2 13,17-19 included pulmonary blood flow (Qp), systemic blood flow (Qs), systemic oxygen delivery (DO 2 ), systemic vascular resistance index (SVRI), and total pulmonary vascular resistance index (PVRI).
Statistical Analysis
Data were summarized as mean Ϯ standard deviation (SD) when continuous, or number and percent when discrete. Oximetric data were excluded during extracorporeal membrane oxygenator (ECMO) support and when the SaO 2 -SvO 2 difference was less than 8%. 13 Exploratory analysis of the SvO 2 -SaO 2 relationship was performed by locally weighted regression, 20 and fractional polynomial regression models were fit for each group. The data were subsequently partitioned into 6 equal-width strata of SaO 2 values from 65% to 90% for quantitative analysis. A 2-way repeated-measures analysis of variance (ANOVA) model was used to test for differences in hemodynamic parameters across intervals of SaO 2 , to test for the effect of phenoxybenzamine, and for the interaction of phenoxybenzamine on the SaO 2 effect. Potential confounding differences in other vasoactive drug doses, FIO 2 , and shunt size, were addressed by entry of these parameters into the model as noninteracting covariates. Post-hoc tests of differences at high SaO 2 were performed with Tukey's wholly significant difference (WSD) correction for multiple comparisons, with significance cutoff at P Ͻ .05 after correction. All analysis was performed with Stata statistical software (StataCorp, College Station, Tex).
Results
Data from 71 patients comprising 2820 patient-hours (mean 40, median 47, range 6 to 48 hours/patient) were analyzed. There were no significant demographic differences between patients managed with phenoxybenzamine (n ϭ 62) or without (n ϭ 9; Table 1 ). Two patients were placed on ECMO support within the first 48 hours for SvO 2 below 25%, metabolic acidosis, and impending cardiovascular collapse, one of whom survived; the overall hospital survival for patients in this study was 68 of 71 or 95.7%. The distributions of SvO 2 and SaO 2 reveal a distinct tail at the lower range for SvO 2 (Figure 1 ). Variation in SvO 2 was much greater than in SaO 2 (SD 10.7 vs 5.5, P Ͻ .0001).
Despite management directed at maintaining SvO 2 greater than 50%, actual SvO 2 was less than the target for 758/2820 hours or 26.8% of the time, and was less than the reported anaerobic threshold of 30% 13 for 52 of 2820 hours or 1.8% of the time. For the 2768 hours without profound venous desaturation, the SaO 2 was out of the usual target range of 70% to 85% for 374 hours or 13.5% of the time. During the periods of hemodynamic deterioration and anaerobic risk, the SaO 2 was in the target range of 70% to 85% for 27 of 52 hours or 52% of the time. Thus, detection of hemodynamic risk by high or low SaO 2 was poor, with a sensitivity of 48%, specificity of 84%, and positive predictive value of only 5%.
The fitted fractional polynomial regressions between SvO 2 and SaO 2 showed distinctly different patterns in the control and phenoxybenzamine groups:
In control patients, the SvO 2 -SaO 2 relationship showed reduction of SvO 2 at both high and low SaO 2 , with a peak at SaO 2 of 77%, in an inverse-square pattern. In patients receiving phenoxybenzamine, the relationship between SvO 2 and SaO 2 was continuously and linearly positive over the range of SaO 2 from 60% to 90%. The mean predictive error was greater in control than phenoxybenzamine groups (Ϯ11.5% vs Ϯ8.3%, P Ͻ .001). The actual data and fitted equations are shown in Figure 2 .
The SaO 2 -SvO 2 relationship was quantitatively assessed (Table 2) . In control patients, this relationship was in fact convex, with maximal SvO 2 occurring at an SaO 2 of 75% to 80%, and with reduced SvO 2 at SaO 2 Ͼ 85% and SaO 2 Ͻ 70% (P Ͻ .01), while in patients receiving phenoxybenzamine, the SvO 2 increased linearly with SaO 2 Ͼ 65% (P Ͻ .001; Figure 3) . In control patients, ⌬Ca-vO 2 increased with SaO 2 Ͼ 80% (P Ͻ .001), while in patients receiving phenoxybenzamine, ⌬Ca-vO 2 was constant at all SaO 2 (P ϭ not significant; Figure 3 ). The SvO 2 was higher, and the ⌬Ca-vO 2 lower, across the whole SaO 2 range with phenoxybenzamine (P Ͻ .0001), and the difference in SvO 2 between groups increased progressively as SaO 2 increased (P Ͻ .0001 by test for trend).
Hemodynamic indices and treatments are summarized in Table 3 . SVR was lower in the phenoxybenzamine group, despite higher nitroprusside doses in the control group and higher norepinephrine doses in the phenoxybenzamine group. Most hemodynamic parameters showed significant variation across intervals of SaO 2 , and differences between treatment groups at high SaO 2 were significant for SvO 2 (P Ͻ .0005), MAP (P Ͻ .0005), Qp/Qs (P Ͻ .0005), SVRI (P Ͻ .0005), PVRI (P Ͻ .0005), and indices of oxygen delivery (P Ͻ .005). Patients receiving phenoxybenzamine had preservation of systemic oxygen delivery at high SaO 2 by stabilization of SVRI, resulting in more balanced Qp/Qs, and a stable reduction in MAP (Figure 4 ).
Discussion
The relationship between SaO 2 and SvO 2 is a complex function of total cardiac output, Qp/Qs, hematocrit, pulmo- and ⌬Ca-vO 2 at intervals of SaO 2 is shown for control and phenoxybenzamine groups. The SvO 2 was higher with phenoxybenzamine across the whole range (P < .02); the SaO 2 effect was highly significant (P < .0001). The ⌬Ca-vO 2 was lower with phenoxybenzamine across the whole range (P < .001); the SaO 2 effect was highly significant (P < .0001). With phenoxybenzamine, the ⌬Ca-vO 2 did not vary with SaO 2 (P ‫؍‬ not significant). Significance was assessed by 2-way repeated measures analysis of variance with adjustment for differences in hemoglobin, FIO 2 , PaCO 2 , shunt size, and doses of dopamine, milrinone, epinephrine, norepinephrine, and nitroprusside as covariates. Significant differences between groups by Tukey WSD post-tests at each SaO 2 interval are signified by *. nary venous saturation, and oxygen consumption. The data provide direct, clinical evidence to validate theoretical models of the critical Qp/Qs and cardiac output dependence of patients after the Norwood operation. The occurrence of systemic vasoconstriction in response to falling systemic perfusion, which will only worsen systemic perfusion in patients with ventricular dysfunction and aortopulmonary runoff, was evident at SaO 2 above 80% in patients managed without phenoxybenzamine-mediated afterload reduction. This situation has traditionally been managed by manipulation of medical gases to raise PVR and lower SVR, using SaO 2 as a rough index of Qp/Qs balance. In control patients, our data confirm the hypothetical deterioration of systemic oxygen delivery associated with high SaO 2 , characterized by a dramatic increase in SVR, reduction in cardiac output, and increase in Qp/Qs. The reduction in cardiac output exceeded the increase in SaO 2 as predicted by modeling, 21 since indices of systemic oxygen delivery fell. Thus, variable Qp/Qs in control patients resulted in a critical range of SaO 2 associated with maximum SvO 2 .
In contrast, patients receiving afterload reduction with phenoxybenzamine did not demonstrate this hemodynamic deterioration at high SaO 2 , instead demonstrating a relatively constant arterial pressure, low SVR, and less variability in Qp/Qs. The hemodynamics in patients receiving phenoxybenzamine tended to behave as predicted by models with constant Qp/Qs and a variable total cardiac output, with both SaO 2 and SvO 2 increasing with cardiac output. The clinical effect was that SaO 2 as high as 90% was not associated with deterioration in SvO 2 . Thus, high SaO 2 resulted, not from high Qp/Qs but from higher cardiac output, in the phenoxybenzamine group. The increasing difference between groups at increasing SaO 2 provides strong evidence for a fundamental alteration in the circulatory determinants of SaO 2 and SvO 2 .
Errors in derived indices such as Qp/Qs and SVRI may result from the limitations imposed by assumptions of pulmonary vein saturation 15 and oxygen consumption. 17, 18 We specifically did not wean FIO 2 to limit SaO 2 and would attempt to reduce work of breathing in unparalyzed patients with low SvO 2 by sedation and ventilator adjustment. No further benefit of pharmacologic paralysis on oxygen consumption has been demonstrated, 19 and no systematic deviations in this clinical approach were evident between groups. Neither of these factors would change the primary finding of the alteration SaO 2 -SvO 2 relationship by phenoxybenzamine.
Although the analysis of clinical data in this study is unique, the early patients in this study have been the subjects of prior investigation. 12, 13 Differential expansion of the size of the treatment group has occurred because we have since administered phenoxybenzamine for all Norwood procedures, except for 2 patients without parental consent for phenoxybenzamine; the resulting imbalance in group size would only reduce the power to detect a statistically significant pharmacologic effect. Because phenoxybenzamine was administered without randomization, the differences between treatment groups could result from existing differences in integrated cardiovascular reflex responses or in treatment variables between patients. However, the groups were highly similar in all factors except for the use of phenoxybenzamine, and the different patterns of response persisted after controlling for differences in other treatment variables.
With continuous recordings of oximetric SvO 2 in the acute postoperative period, we have demonstrated rapid deterioration in SvO 2 associated with systemic vasoconstriction in patients not receiving phenoxybenzamine. 12 Since norepinephrine is the postganglionic sympathetic neurotransmitter, ␣-adrenergic blockade would be expected to blunt the profound sympathetic vasomotor responses observed in high-risk neonates undergoing complex cardiovascular procedures.
14 Although other drugs may be as effective as phenoxybenzamine in reducing SVR under resting conditions, we did not achieve similar results in the control group with routine use of milrinone and sodium nitroprusside.
The perioperative medical management of these patients requires synthesis of information from multiple sources to derive management decisions, which may involve compromise between competing goals. Our vasoactive drug strategy used milrinone for post-␤ receptor amplification of inotropy and vasodilation, and dopamine for dopaminergic effects only. A fixed dose of phenoxybenzamine was administered on CPB to all patients in the phenoxybenzamine group to block ␣-adrenergic vasoconstriction, and titration of short-acting drugs to modify SVR was necessary. We used epinephrine and norepinephrine liberally to modify SVR and to provide potent inotropy, and occasionally added low-dose nitroprusside for additional vasodilation. We added an infusion of phenoxybenzamine in 46 of 62 patients in the phenoxybenzamine group if the postoperative hemodynamic pattern showed a need for more consistent SVR reduction. Through multiple stepwise manipulations, the medication mixture could become complex in some patients, and this study did not specifically address strategies to simplify vasoactive drug use. However, our data suggest that ␣-adrenergic blockade is a more effective approach to modify the intense sympathetically mediated vasomotor responses in these infants, and the use of a very long-acting drug like phenoxybenzamine commits the patient to a treatment strategy based on sustained SVR reduction. Optimization of hemodynamics by control of SVR, as predicted in a mathematical model of post-Norwood circulation, 22 was confirmed by our data.
The data also provide direct evidence of the poor predictive value of SaO 2 for systemic oxygen delivery, as predicted from theoretical models, 11, [21] [22] [23] and emphasizing the importance of continuous SvO 2 monitoring [11] [12] [13] to indicate systemic oxygen status. A priori, we did not anticipate any predictable relationship between SaO 2 and SvO 2 ; instead, we relied on continuous SvO 2 measurement to guide management aimed at provision of adequate oxygen delivery. Even in the phenoxybenzamine group, only 32% of the SvO 2 variance could be explained by SaO 2 ; therefore, we do not advocate acute postoperative management of these patients without SvO 2 monitoring.
The findings of the current study support management strategies based on the measurement and maximization of SvO 2 , given the poor predictive value of SaO 2 for SvO 2 . The data provide support both for management strategies such as intentional hypercapnia 24 to raise PVR when SVR is relatively uncontrolled, and for pharmacologic control of SVR with phenoxybenzamine. With the latter strategy, higher SaO 2 is not deleterious, and is typically associated with improved systemic oxygen delivery.
